Steven A. Shallcross
CEO and CFO at Theriva Biologics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Theriva Biologics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Theriva Biologics Inc. August 3, 202666.6%
-
Theriva Biologics Inc. August 29, 202587.2%
-
Theriva Biologics Inc. October 31, 202485.9%
-
Theriva Biologics Inc. October 2, 202376.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 7, 2023 | Theriva Biologics Inc. | Open-market purchase | +14,000 | $0.69 | $9,660 |
| Jun 6, 2023 | Theriva Biologics Inc. | Open-market purchase | +26,000 | $0.63 | $16,380 |
| Feb 10, 2023 | Theriva Biologics Inc. | Open-market purchase | +25,000 | $1.04 | $26,000 |
| Feb 2, 2023 | Theriva Biologics Inc. | Open-market purchase | +25,000 | $0.94 | $23,500 |
| Jan 25, 2023 | Theriva Biologics Inc. | Open-market purchase | +25,000 | $0.87 | $21,750 |
| Jan 20, 2023 | Theriva Biologics Inc. | Open-market purchase | +25,000 | $0.75 | $18,750 |
| Dec 29, 2022 | Theriva Biologics Inc. | Open-market purchase | +100,000 | $0.44 | $44,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.